


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

**VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE NOMINATES NEXT-GENERATION SMALL
MOLECULE GIPR ANTAGONIST FOR POTENTIAL INTERVENTION OF
OBESITY AND RELATED DISORDERS**

This announcement is made by InSilico Medicine Cayman TopCo (the “**Company**”, together with its subsidiaries, the “**Group**” or “**InSilico Medicine**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that, driven by the proprietary generative AI platform of InSilico Medicine, the Company has nominated ISM1354, a potential best-in-class next-generation small molecule Glucose-dependent Insulinotropic Polypeptide Receptor (GIPR) antagonist, as a preclinical candidate (PCC) for the potential intervention of obesity, as well as obesity-related disorders including type 2 diabetes, with the potential to expand into cardiovascular diseases.

In January of this year, the Company announced the nomination of another GIPR antagonist, ISM0676, which demonstrated up to a 31.3% weight loss in combination with Semaglutide in humanized mouse models. In comparison, the newly nominated PCC not only retains excellent drug-like properties but also achieves multi-dimensional optimization across pharmacokinetics (PK) and safety profiles.

To date, InSilico Medicine has announced the nomination of ten PCCs in the first nine months of 2026, breaking the Company’s historical record for annual pipeline output pushing the total number of PCCs nominated since 2021 to 34, thereby validating the R&D efficiency of generative AI through reproducible, real-world examples.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, September 30, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Chuen Yan Leung, Ph.D. as non-executive director; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.